ERBB2 and breast cancer: Interestingly, stratification of this analysis by breast cancer receptor subtype demonstrated that the observed association was limited to the most traditionally indolent subtype (hormone receptor–positive and ERBB2-negative; OR, 1.12; 95% CI 1.04–1.21).